# Healthequity, Inc.: Form 10-Q for the period ended Oct 31, 2024

- Company: [Healthequity, Inc.](/companies/hqy.md) (CIK 1428336)
- Form: 10-Q
- Filed: 2024-12-09
- Accepted by EDGAR: Dec 9, 2024, 21:03 ET
- Period: 2024-10-31
- Accession: 0001428336-24-000110
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1428336/000142833624000110/hqy-20241031.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1428336/000142833624000110/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-10-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-08-01 to 2024-10-31 | $300.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-02-01 to 2024-10-31 | $888.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-08-01 to 2024-10-31 | $103.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-02-01 to 2024-10-31 | $299.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-08-01 to 2024-10-31 | $197.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-02-01 to 2024-10-31 | $588.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-08-01 to 2024-10-31 | $60.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2024-02-01 to 2024-10-31 | $174.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-08-01 to 2024-10-31 | $19.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-02-01 to 2024-10-31 | $120.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-08-01 to 2024-10-31 | $18.2m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2024-02-01 to 2024-10-31 | $45.4m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2024-08-01 to 2024-10-31 | $515.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-02-01 to 2024-10-31 | $15.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-08-01 to 2024-10-31 | $5.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-02-01 to 2024-10-31 | $70.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-08-01 to 2024-10-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-02-01 to 2024-10-31 | $0.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-08-01 to 2024-10-31 | $0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-02-01 to 2024-10-31 | $0.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-08-01 to 2024-10-31 | 88,634,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-02-01 to 2024-10-31 | 88,699,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-02-01 to 2024-10-31 | $264.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-02-01 to 2024-10-31 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2024-02-01 to 2024-10-31 | $58.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-10-31 | $322.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-10-31 | $495.2m | us-gaap:AssetsCurrent |
| Total assets | at 2024-10-31 | $3.49bn | us-gaap:Assets |
| Current liabilities | at 2024-10-31 | $154.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-10-31 | $1.36bn | us-gaap:Liabilities |
| Long-term debt | at 2024-10-31 | $1.08bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-10-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-10-31 | $2.12bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1428336/000142833624000110/hqy-20241031.htm

Filed Dec 9, 2024.
Source: SEC EDGAR, the filing index for accession 0001428336-24-000110. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.